Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

Phase 1approved[²²⁵Ac]Ac-FL-261Positive

AI Analysis

Summary

Full-Life Technologies announced FDA IND clearance and Australian regulatory approval to initiate a Phase 1 clinical trial for [²²⁵Ac]Ac-FL-261, an actinium-based radiopharmaceutical candidate.

Clinical Trial Data

Phase

Phase 1

Outcome Details

FDA IND clearance and Australian regulatory clearance

Importance:6/10

Sentiment:

0.80

IND clearanceradiopharmaceuticalactinium-basedFDA approvalclinical trial initiation

Related Companies

$INBP $GBCYD

Read the original article

Published by PR Newswire Biotech on September 9, 2026 12:25 PM

Read Original